Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

ABSTRACT Tislelizumab is a next‐generation PD‐1 monoclonal antibody developed to overcome the limitations of earlier immune checkpoint inhibitors. By eliminating Fcγ receptor binding, it avoids macrophage‐mediated T‐cell clearance and enhances the antitumor immune response. Unlike conventional PD‐1...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-09-01
coleção:	Chronic Diseases and Translational Medicine
Assuntos:	monoclonal antibodies, immunotherapy PD‐1 tislelizumab
Acesso em linha:	https://doi.org/10.1002/cdt3.70017
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!